A subset analysis of efficacy and safety outcomes from phase 3 clinical studies of ixekizumab for the treatment of patients with severe plaque psoriasis.
Saved in:
| Title: | A subset analysis of efficacy and safety outcomes from phase 3 clinical studies of ixekizumab for the treatment of patients with severe plaque psoriasis. |
|---|---|
| Authors: | Spelman L; Veracity Clinical Research, Brisbane, Australia., Rubel D; Woden Dermatology, ACT, Australia., Brnabic A; Eli Lilly Australia Pty Limited, West Ryde, Australia., Burkhardt N; Eli Lilly Australia Pty Limited, West Ryde, Australia., Riedl E; Eli Lilly Ges.m.b.H, Vienna, Austria.; Department of Dermatology, Medical University of Vienna, Vienna, Austria., Foley P; Skin Health Institute, Carlton, Australia.; The University of Melbourne, St Vincent's Hospital Melbourne, Fitzroy, Australia. |
| Source: | The Journal of dermatological treatment [J Dermatolog Treat] 2022 Feb; Vol. 33 (1), pp. 329-335. Date of Electronic Publication: 2020 Apr 21. |
| Publication Type: | Clinical Trial, Phase III; Journal Article |
| Journal Info: | Publisher: Informa Healthcare Country of Publication: England NLM ID: 8918133 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1471-1753 (Electronic) Linking ISSN: 09546634 NLM ISO Abbreviation: J Dermatolog Treat Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
